Date: 2016-06-30
Type of information: Nomination
Compound:
Company: Epigenomics (Germany - USA)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 30, 2016, Epigenomics announced that the Supervisory Board appointed Gregory Hamilton as Chief Executive Officer with effect from July 1, 2016. Mr. Hamilton, who has held senior management positions in the U.S. molecular diagnostics industry, will succeed Dr. Thomas Taapken.
Mr. Hamilton, (46), has over 20 years of management experience in molecular diagnostics, manufacturing and professional service industries. Prior to joining Epigenomics, Mr. Hamilton was Chief Executive Officer & Director of AltheaDx Inc., Chief Operating Officer and Chief Financial Officer of Enigma Diagnostics Inc., Vice President of Operations and Finance at Third Wave Technologies Inc. and Vice President of Operations at Hologic Inc. He has been responsible for multiple FDA-cleared products including a Human Papilloma Virus (HPV) High Risk Screening assay and the first ever cleared HPV genotyping assay. Mr. Hamilton received his MBA from the University of Chicago and his Bachelor of Science in Finance from Purdue University.
Dr. Thomas Taapken, who has served in the dual role of CEO and CFO since 2012, will now leave the company. The vacant CFO position will be filled shortly.
Financial terms:
Latest news:
